Arvinas logo

Brad Margus, M.B.A

Mr. Margus is Co-Founder and Chief Executive Officer (CEO) of Cerevance, a venture-backed, clinical-stage drug development company focused on pursuing novel targets for brain diseases. Prior to Cerevance, Mr. Margus also served as the CFO of Envoy Therapeutics, where he raised $8 million from investors, employed a unique technology to discover new compounds for brain diseases, and sold the company within three years for $140 million. Additionally, Mr. Margus was CFO of Perlegen Sciences, a leader in analyzing genetic variation that raised $257 million from investors, exceeded $100 million in revenues, and identified diagnostic markers for disease risk and drug response.

Mr. Margus has been a member of numerous government advisory committees as well as corporate and nonprofit boards. He currently serves on the boards of Second Genome, Presage Biosciences and the non-profit A-T Children’s Project. Additionally, he serves as the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH.

Skip to content